In this work, we have demonstrated, to our knowledge, for the first time that when colon cancer cells acquire resistance to oxaliplatin a change in Fas functionality develops, and a receptor switch occurs: from activation of apoptosis to stimulation of MAPK pathways. The gene discussed is FAS; the disease is malignant colon neoplasm.